PMVP stock forecast, quote, news & analysis
PMV Pharmaceuticals Inc is a precision oncology company... Show more
Why PMV Pharmaceuticals (PMVP) Stock Is Down -15% in the Last 30 Days
Key Takeaways
- PMV Pharmaceuticals shares declined roughly 15% over the last 30 days, falling from about $1.49 on October 8 to $1.26 by November 6.
- The pullback followed a sharp late-September and early-October rally, with profit-taking and an equity-dilution overhang weighing on sentiment.
- Over the last quarter, the stock is still up about 6%, reflecting the strength of rezatapopt's clinical data earlier in the period.
- PMV is a precision oncology company advancing rezatapopt, an oral small molecule targeting the TP53 Y220C mutation, with an NDA submission planned for the first quarter of 2027.
- Upcoming catalysts include a late-breaking presentation at ENA 2026 and further pivotal Phase 2 PYNNACLE data.
- Investors can find additional detail on Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading tools are tracking stocks like PMVP.
PMV Pharmaceuticals (PMVP) Company Overview and Market Position
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) is a precision oncology company headquartered in Princeton, New Jersey, focused on the discovery and development of small-molecule therapies that target p53, a tumor-suppressor protein often described as the "guardian of the genome." The company's lead candidate, rezatapopt, is an orally available small molecule designed to structurally correct the mutant p53 protein associated with the Y220C mutation, restoring its cancer-fighting function.
PMV's tumor-agnostic approach is aimed at treating a range of advanced solid tumors driven by TP53 Y220C mutations, including platinum-resistant ovarian cancer. The company is preparing to submit a New Drug Application (NDA) seeking accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027. Investors follow PMVP closely for its clinical data readouts, regulatory milestones, and commercial launch preparation.
PMV Pharmaceuticals (PMVP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PMVP shares fell from a closing price of approximately $1.49 on October 8 to $1.26 on November 6, a decline of about 15%. The move reversed much of a strong rally that had carried the stock from near $1.21 at the end of August to a local peak around $1.79 in early October.
The broader quarterly picture remains more constructive. Measured from the close of roughly $1.19 on August 7, the stock is still up about 6% over the last three months. In other words, the recent 30-day pullback has trimmed, but not erased, the gains built earlier in the quarter as positive rezatapopt data and analyst support lifted investor confidence.
What Drove PMVP Stock Price in the Last 30 Days
The last 30 days were shaped primarily by a retreat from overextended short-term levels rather than a single negative fundamental event. After surging on encouraging rezatapopt interim ovarian cancer data and bullish analyst commentary in late September, PMVP entered October with substantial momentum. As the stock consolidated, profit-taking emerged, and shares gave back a meaningful portion of the prior run.
A lingering overhang has been shareholder dilution. In early September, PMV priced an oversubscribed $50 million public offering of common stock, pre-funded warrants, and accompanying warrants at $1.21 per share. The expanded share count continues to weigh on sentiment even as it strengthens the company's cash position. Small-cap biotech volatility, combined with thin trading liquidity, also amplified the downside drift into early November. The company's November 4 announcement that pivotal Phase 2 rezatapopt PYNNACLE data would be featured in a late-breaking oral presentation at ENA 2026 provided a forward-looking catalyst, though shares remained under pressure through the period.
What Drove PMVP Stock Performance Over the Last Quarter
The quarterly trend tells a broader story of clinical progress outweighing financing concerns. In late August, PMV announced updated promising rezatapopt monotherapy interim ovarian cancer data from the pivotal Phase 2 PYNNACLE trial, followed by the pricing of its $50 million offering. Wall Street analysts responded with buy ratings and price targets near $4.00, contributing to a rally that pushed shares from roughly $1.19 in early August to above $1.75 by the start of October.
Supporting the longer-term narrative, the company appointed a Chief Commercial Officer in September to prepare for a potential rezatapopt launch and added a healthcare-investing veteran to its board in October. These steps reflect PMV's transition from a clinical-stage developer toward a commercially focused organization, even as the stock's recent pullback highlights the inherent volatility of pre-revenue biotech names.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of these bots trading thousands of tickers, but only the top-performing and most relevant strategies appear in this section. The bots vary widely in approach, timeframe, and performance metrics, allowing traders to explore tools suited to different styles and risk preferences. For investors tracking volatile names such as PMVP, reviewing these AI-driven signals can add another layer of perspective to their analysis.
PMVP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors that could shape PMVP's path. The pivotal Phase 2 rezatapopt PYNNACLE data presented at ENA 2026 and any subsequent data readouts remain the central clinical catalysts. Progress toward the planned NDA submission for accelerated approval in platinum-resistant/refractory ovarian cancer in the first quarter of 2027 is equally important.
Additional items worth watching include quarterly financial results and cash runway, the pace of commercial build-out under the new Chief Commercial Officer, and any further financing that could affect dilution. Broader conditions—including risk appetite for small-cap and pre-revenue biotechnology companies—will also influence near-term price action. As with all clinical-stage oncology companies, trial outcomes and regulatory decisions carry inherent uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PMVP's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for PMVP moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 18 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 55 cases where PMVP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMVP as a result. In 90 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PMVP turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PMVP moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PMVP crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMVP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PMVP entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMVP advanced for three days, in 206 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.942) is normal, around the industry mean (3.498). P/E Ratio (-0.887) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. PMVP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMVP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology